In everyday clinical care of chronic diseases, obesity-mediated metabolic dysregulation has become a core risk factor for the high and increasingly earlier onset of chronic disease in China. Traditional treatment models centered on individual disease entities can no longer cope with the current compound, normalized national chronic-disease burden. At the 2026 Obesity Conference (COC 2026), Prof. Hongbing Shen — Vice Minister of China’s National Health Commission, Director of the National Disease Control and Prevention Administration, and Academician of the Chinese Academy of Engineering — together with Prof. Johanna Ralston, CEO of the World Obesity Federation (WOF), drew on the local epidemic situation and the national prevention system, and on global obesity trends and the latest international advances, respectively, to systematically map the pain points and directions of prevention and treatment for obesity-related chronic disease. Their reports provide authoritative academic reference for domestic clinicians seeking source-level prevention, multi-disease co-management and full-cycle intervention.
A Severe Local Chronic-Disease Burden: Obesity Has Become a Core Risk Factor for Chronic Disease in China
Prof. Shen cited data from the 2023 Global Burden of Disease study (GBD 2023) and China’s national chronic-disease and risk-factor surveillance. The data show that in 2023 chronic diseases caused 9.55 million deaths in China and 326 million disability-adjusted life years (DALYs); cardiovascular and cerebrovascular disease (stroke, ischemic heart disease), chronic obstructive pulmonary disease and cancer are the leading causes. In addition, the share of deaths in China attributable to non-communicable diseases (NCDs) rose from 74.3% in 1990 to 89.2% in 2023, and chronic disease has become the leading cause of death — a fundamental shift in the country’s cause-of-death profile.
In terms of risk-factor attribution for chronic disease, hypertension, smoking, outdoor particulate-matter pollution, high blood glucose and high LDL-C cholesterol sit at the top of the list. Of particular note, overweight/obesity — as captured by high body-mass index (BMI) — has entered the core cluster of metabolism-related risk factors. Metabolic risk factors are also showing a marked shift toward younger populations: the prevalence of obesity and metabolic dysregulation is rising continuously among middle-aged and younger adults, breaking the traditional pattern in which chronic disease was mainly an older-age phenomenon.
National chronic-disease and risk-factor surveillance data further show that in 2023 the combined prevalence of overweight and obesity among Chinese adults reached 57.0%, with the overweight rate up 4.5 percentage points and the obesity rate up 6.0 percentage points from 2013. The situation among children and adolescents is even more striking: among those aged 6–17, one in four is overweight or obese. This earlier-life epidemic of obesity directly increases the risk of metabolic diseases such as hypertension and type 2 diabetes in middle-aged and younger populations, generating a vicious cycle in the metabolic-disease onset chain.
China’s Prevention System Has Evolved: From Clinical Treatment to Comprehensive Prevention
In the face of a worsening obesity and chronic-disease epidemic, China’s prevention system has gone through decades of iteration, gradually shifting from a model centered on clinical treatment to a whole-population, full-cycle comprehensive approach. Prof. Shen outlined three key stages. Stage 1 (late 1950s to 1993) focused on clinical medical treatment — terminal-stage interventions only, with population-level prevention still blank. Stage 2 (1994 to 2006) brought public health and clinical medicine on equal footing, with a domestic public-health prevention system initially established. Stage 3 (2007 to the present) has seen further integration of public health and clinical medicine, supported by a series of public policies that have driven population-wide prevention and roughly shaped the integrated chronic-disease prevention framework.
In terms of prevention targets, the “Healthy China 2030”Plan sets clear goals: raise average life expectancy from 76.3 years in 2015 to 79.0 years in 2030, and reduce premature mortality from major chronic diseases by 30% relative to 2015. Prof. Shen noted that during the 14th Five-Year Plan period, a digital surveillance network, a pre-hospital/in-hospital integrated emergency green channel, and standardized management mechanisms for chronic-disease patients (e.g., hypertension and diabetes) have been established. A trinity of "professional public-health institutions + general/specialty hospitals + primary medical institutions" for major-disease prevention has gradually taken shape, advancing the full pipeline of early screening, early diagnosis and early treatment of chronic disease.
Looking ahead to the 15th Five-Year Plan, the Recommendations of the Central Committee of the Communist Party of China on Formulating the 15th Five-Year Plan for National Economic and Social Development explicitly proposes implementing a “health-priority development strategy,” focusing on key risk factors such as obesity, smoking and hypertension, and shifting chronic-disease prevention from “passive treatment” to “active prevention.” Prof. Shen emphasized that, going forward, prevention must drive a multi-institution chain of prevention, treatment and health management — drawing on disease-control agencies, hospitals, primary health-service institutions, research institutes, social organizations and enterprises — and must place lifestyle intervention as the priority area for chronic-disease prevention. Core health indicators in China have been improving steadily: average life expectancy has risen from 76.6 years in 2016 to 79.25 years in 2025, and residents’ health literacy has risen from 11.58% to 33.69%, laying the foundation for subsequent precision prevention and treatment of obesity and chronic disease.
A Global View: Obesity-Related Chronic Disease Is Already a Worldwide Public-Health Crisis
The local Chinese picture is a partial reflection of the global chronic-disease crisis. Prof. Johanna Ralston, CEO of the World Obesity Federation, brought a global perspective that further underscored the strategic importance of regions such as China, in Asia, in obesity prevention. She noted that since 1980 the global prevalence of adult obesity has roughly doubled, and that the number of overweight or obese people worldwide has now exceeded 2.7 billion; the global obesity population is projected to keep growing through 2035, further intensifying global chronic-disease prevention pressure.
Prof. Ralston specifically highlighted that childhood and adolescent obesity is highly prevalent globally, and that in China the obesity rates of boys and girls are converging — posing long-horizon, larger-base chronic-disease risk for the population. She also stressed that, although the rate of increase in global obesity prevalence is slowing, the harm caused by obesity-related chronic disease continues to expand, and that existing routine interventions are unlikely to reverse the growth trend in the short term — meaning obesity prevention requires global coordination and sustained, systematic action.
On the treatment frontier, Prof. Ralston introduced several important developments: in December 2025, the WHO approved its GLP-1 guideline, providing guidance for obesity management under different health-system and resource conditions; new applications for incretin-based therapies are expected to be expanded by 2027. She also emphasized that obesity prevention must fully incorporate the real-life experience and actual needs of patients with obesity, engaging patients in policy discussions so that prevention strategies are grounded not only in epidemiological data but also in the realities of patients’ lives and psychological needs — thereby advancing a genuinely patient-centered model of clinical care.
Conclusion
Together, the two speakers’ reports constructed a “local action + global vision” framework for understanding obesity-related chronic-disease prevention. Prof. Ralston noted that the chronic-disease epidemic driven by obesity is a long-term, severe public-health challenge; although mature interventions already exist, fundamentally reversing population-level incidence curves will require long-term, coordinated, whole-of-society effort. Prof. Shen emphasized in his closing that future clinical work must align closely with national prevention strategy and with global prevention consensus, move beyond a single-disease mindset, focus on obesity as the central upstream risk factor, strengthen obesity screening, lifestyle intervention and metabolic management across all age groups, and implement simultaneous, full-course prevention and control of obesity, hypertension, diabetes and other conditions — with the goal of reducing China’s chronic-disease burden at its root and helping achieve the “Healthy China 2030”prevention targets.